London.- UK recommended using other non-Oxford vaccines /AstraZeneca to people under the age of 30, after a possible link between it and unusual thrombi was detected in young adults, the Joint Committee on Vaccination and Immunization (JCVI) announced Wednesday.
This population group will have the option of choosing to be vaccinated with Pfizer and Moderna preparations, also approved in this country, although regulators continue to recommend the AstraZeneca vaccine in older adults considering that “the benefits more than outweigh the risks.”
79 cases of thrombosis have been registered
In a joint press conference, the CEO of the UK Medicines and Healthcare Products Regulatory Agency (MHRA), June Raine, explained that as of March 31, 79 cases of low platelet count thrombosis have been recorded in people. who received the first dose of the preparation from the University of Oxford.
Of these, 19 people have died, three of them under 30 years old – although in some cases the cause is unknown.
Of the total affected, between 18 and 79 years old, 51 are women and 28 men, Raine said.
Use of the Oxford / AstraZeneca vaccine
The JCVI explained that it continues to recommend use of the Oxford / AstraZeneca vaccine in those over 30 years of age because the risk of becoming seriously ill or dying from covid-19 is “higher” than that of developing these unusual thrombi, which remain “rare” in the population as a whole.
On the contrary, for those under 30 years of age without underlying pathologies, the risk from the coronavirus is lower and therefore it is advisable to avoid that possible rare side effect that the AstraZeneca vaccine presents and to offer them alternatives “if available”.
Young people will still be able to choose the prepared from Oxford, which is more widespread, if they prefer to be vaccinated quickly.
Healthcare sector or people with a weakened immune system
The Committee also clarifies that young people under 30 years of age from priority groups, such as the health sector or people with a weakened immune system, who have received a first dose of the oxford vaccine they should receive the second according to the schedule.
For its part, the European Medicines Agency (EMA, in English) confirmed today a “possible link” of AstraZeneca with the cases of thrombus reported in some people who received this vaccine, but considers that its benefit continues to be “above” the risk of a side effect.
On Tuesday, the University of Oxford halted clinical trials it conducts with its vaccine, developed with the pharmaceutical company AstraZeneca, in children and adolescents until the MHRA decision announced today.
The provisional arrest of this study comes at a time when mistrust is growing in the United Kingdom towards the Oxford / AstraZeneca preparation, which have already received the majority of the 31.6 million Britons inoculated with a first dose.
The Government has urged all citizens to continue to go to be vaccinated when they are summoned, whether to receive the injection of AstraZeneca, that of Pfizer or, as of today, also that of Moderna, the three approved in the country.
With information from EFE